Related Experiment Video

Updated: Dec 8, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.2K

AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm

Sebastiano Gangemi1, Alessandro Tonacci2

  • 1School and Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University Hospital "G. Martino", Via Consolare Valeria SNC, 98125 Messina, Italy.

Cytokine & Growth Factor Reviews
|September 17, 2020
PubMed

Insights

AntagomiRs offer a promising, safe treatment for severe COVID-19 by targeting the cytokine storm. This approach could also benefit other coronavirus infections, complementing vaccine distribution efforts.

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • COVID-19 causes a severe cytokine storm, leading to lung damage and death.
  • Current therapies targeting specific cytokines like IL-6 are insufficient to block the entire storm.
  • Severe COVID-19 patients experience significant lung injury due to uncontrolled inflammation.

Purpose of the Study:

  • To explore antagomiRs as a potential treatment for the COVID-19 cytokine storm.
  • To evaluate the safety and efficacy of antagomiRs in managing severe COVID-19.
  • To assess the applicability of antagomiRs to other coronavirus-associated diseases.

Main Methods:

  • Review of existing data on antagomiR efficacy and safety in cardiovascular disease.
  • Analysis of the cytokine storm mechanism in COVID-19.
  • Conceptualization of antagomiR customization for specific viral infections.

Main Results:

  • AntagomiRs have demonstrated safety and efficiency in cardiovascular disease treatment.
  • The cytokine storm in COVID-19 involves complex cytokine interactions.
  • AntagomiRs can be customized to target specific disease-related molecules.

Conclusions:

  • AntagomiRs represent a viable and safe therapeutic alternative for managing the COVID-19 cytokine storm.
  • This approach offers potential benefits for severe COVID-19 patients and other coronavirus outbreaks.
  • AntagomiR therapy can be tailored to disease-specific needs, enhancing treatment effectiveness.
Keywords:
ARDSCOVID-19CoronavirusCytokine stormantagomiRsmicroRNAs

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

930
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
94
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
161
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.5K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.0K